Apoimmune, Inc.

Louisville, KY 40204

SBIR Award Summary

Total Number of Awards 14
Total Value of Awards $5.46MM
First Award Date 05/01/02
Most Recent Award Date 09/01/11

Key Personnel

Last Name Name Awards Contact
Shirwan Haval Shirwan 7
Mcclure G D Mcclure 1
Huseby Rolf M Huseby 3
Eckhoff Devin E Eckhoff 3
Macleod Kathryn J. Macleod 8

14 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 09/01/11 - 08/31/13

DESCRIPTION (provided by applicant): Pancreatic islet transplantation is a viable approach for the treatment of type 1 diabetes (T1D). However, this therapeutic approach suffers from graft rejection. Dr. Shirwan, founder of ApoImmune, has developed a novel immunotherapeutic approach aimed at tolerance induction to alloantigens without chronic u...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 09/01/11 - 08/31/13

DESCRIPTION (provided by applicant): Pancreatic islet transplantation is a viable approach for the treatment of type 1 diabetes (T1D). However, this therapeutic approach suffers from graft rejection. Dr. Shirwan, founder of ApoImmune, has developed a novel immunotherapeutic approach aimed at tolerance induction to alloantigens without chronic u...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 09/05/10 - 08/31/11

DESCRIPTION (provided by applicant): Pancreatic islet transplantation is a viable approach for the treatment of type 1 diabetes (T1D). However, this therapeutic approach suffers from graft rejection. Dr. Shirwan, founder of ApoImmune, has developed a novel immunotherapeutic approach aimed at tolerance induction to alloantigens without chronic u...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-135
Budget: 09/01/09 - 08/31/11

DESCRIPTION (provided by applicant): The objective of this NIAID Advanced STTR Phase I proposal is to combine the strengths of academic investigators from the fields of immunology and animal disease modeling with the resources of ApoImmune Inc. to develop a novel vaccine, ApoVax104-TB" targeting both active and latent Tuberculosis (TB) infection...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 08/01/09 - 07/31/11

DESCRIPTION (provided by applicant): Cervical cancer is one of the most common cancers affecting women and is a worldwide health problem. Unlike most cancers, cervical cancer is caused by a virus - the human papillomavirus (HPV). Two preventative vaccines against HPV were recently licensed in the United States. Merck &Co. developed a vaccine ca...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-35
Budget: 09/01/08 - 08/31/09

DESCRIPTION (provided by applicant): The objective of this NIAID Advanced STTR Phase I proposal is to combine the strengths of academic investigators from the fields of immunology and animal disease modeling with the resources of ApoImmune Inc. to develop a novel vaccine, ApoVax104-TB" targeting both active and latent Tuberculosis (TB) infection...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 08/01/08 - 07/31/09

DESCRIPTION (provided by applicant): Cervical cancer is one of the most common cancers affecting women and is a worldwide health problem. Unlike most cancers, cervical cancer is caused by a virus - the human papillomavirus (HPV). Two preventative vaccines against HPV were recently licensed in the United States. Merck & Co. developed a vaccine c...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-06-21
Budget: 09/06/07 - 03/05/09

DESCRIPTION (provided by applicant): The main objective of this proposal is to develop a novel cancer vaccine, ApoVax-SVN(tm) based on the use of a proprietary costimulatory chimeric ligand, 4-1BBL, designed to specifically deliver survivin, a tumor associated antigen (TAA) to professional antigen-presenting cells (APCs) and activate them for th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-21
Budget: 08/06/07 - 01/31/09

DESCRIPTION (provided by applicant): Type 1 Diabetes (T1D) is an autoimmune disease that targets insulin secreting pancreatic beta cells for destruction and remains a major cause of morbidity and mortality in over 1% of the population worldwide. Although insulin therapy and islet transplantation are currently the most effective treatments, both ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 07/31/07 - 07/31/08

DESCRIPTION (provided by applicant): Various cancer vaccines based on tumor associated antigens (TAAs) or tumor specific antigens (TSAs) have shown efficacy in preclinical models. However, their therapeutic efficacies have been rather limited in clinical trial settings. Although the reason for clinical inefficacy for these vaccines is not known...

Load More